Cellomatics Biosciences Limited
CELLOMATICS BIOSCIENCES LTD
10 Colwick Quays Business Park,
Road No 2,
Tel: 07881 348359
LinkedIn: Cellomatics Biosciences Ltd
- 2022 International Trade
Cellomatics Biosciences supports pharmaceutical and biotechnology companies to expedite the successful development of new therapies by developing innovative solutions using its specialist scientific and therapeutic expertise.
Founded in 2015 by Dr Shailendra Singh, Cellomatics Biosciences is a Nottingham-based Contract Research Organisation (CRO) that provides pre-clinical invitro testing services for biotechnology and pharmaceutical clients as part of new drug development programmes.
Renowned for its tailored approach to novel molecules, the company has built internal expertise in a range of therapeutic areas, with specific focuses on oncology, immuno- oncology, immunology, inflammation and respiratory.
Cellomatics offers a range of specialist services, including cell biology assays, phenotypic screening, analytical assays, molecular assays, contract cell culture and customised assay development.
A period of growth
Since its inception, the team has grown in both numbers and experience and is now made up of 15 employees, all qualified to PhD or higher degree standard. Previously based at BioCity Nottingham, Cellomatics has since moved into purpose-built premises in Colwick, Nottingham, representing a three-fold increase in its footprint and allowing room for further expansion. Its laboratories are equipped with state-of-the-art imaging and analysis equipment and Class ll biological safety cabinets, fridges, freezers andCO2 incubators.
The company is based at the heart of the UK’s pre-clinical CRO sector in the East Midlands, which affords access to talent and expertise from the local universities and the thriving scientific community.
Since it was founded, Cellomatics has supported over 200 projects for more than 70 clients in 17 countries, achieving close to 50 per cent year-on-year revenue growth over the past three years. The business works closely with clients to develop bespoke assays and deliver data for that part of a drug’s pre-clinical journey. This consultative approach has cumulated in repeat business, client recommendations and a reputation of excellence, resulting in strong growth and a global client base from early-stage biotech companies through to major pharma companies.
As a result of the pandemic, Cellomatics saw an increase in demand for its services in relation to SARS-CoV-2 testing, and now offers an enzyme-based binding bioassay to screen compounds that may interfere with the binding of the COVID spike protein and ACE2 receptor.
The company’s global client network extends from the Far East including Japan, South Korea, Singapore, Hong Kong and India to the West, across the US and Canada. From 2018 to 2020,Cellomatics’ overseas trade increased by 208 per cent, representing an average year-on-year growth of 76 per cent. Repeat business is a key factor in sustaining this growth, and the company has seen this increase year-on-year from 15 per cent in 2018 to 55 per cent in 2020.
Cellomatics has ambitious plans to further diversify its client base by tapping into the growing global drug development market and areas of unmet need for new treatments, with a particular focus on markets in the US and EU.
By understanding global trends and continuing to adapt its service offering to meet demands, Cellomatics anticipates up to 75 percent of its total revenue will come from overseas in the next two to three years. This growth trend is expected to continue, with an increasing number of clients coming to Cellomatics from overseas for the company’s bespoke, innovative, and practical approach to drug discovery projects.